KCNN4 and atherosclerosis: Since, as mentioned above, KCa3.1 channel inhibition has been shown to decrease atherosclerosis development in Apoe−/− mice, KCa3.1 blockers and KCa3.1 activators ideally should be compared side-by-side in the same animal experiment and in the same environment in order to determine whether both approaches indeed have therapeutic benefits and whether one approach is superior to the other.